1
|
Shortt G, Shortt N, Bird G, Kerse K, Lieffering N, Martin A, Eathorne A, Black B, Kim B, Rademaker M, Reiche L, Paa ST, Harding S, Armour M, Semprini A. Mānuka oil based ECMT-154 versus vehicle control for the topical treatment of eczema: study protocol for a randomised controlled trial in community pharmacies in Aotearoa New Zealand. BMC Complement Med Ther 2024; 24:61. [PMID: 38287323 PMCID: PMC10823637 DOI: 10.1186/s12906-024-04358-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 01/14/2024] [Indexed: 01/31/2024] Open
Abstract
BACKGROUND Eczema is a chronic, relapsing skin condition commonly managed by emollients and topical corticosteroids. Prevalence of use and demand for effective botanical therapies for eczema is high worldwide, however, clinical evidence of benefit is limited for many currently available botanical treatment options. Robustly-designed and adequately powered randomised controlled trials (RCTs) are essential to determine evidence of clinical benefit. This protocol describes an RCT that aims to investigate whether a mānuka oil based emollient cream, containing 2% ECMT-154, is a safe and effective topical treatment for moderate to severe eczema. METHODS This multicentre, single-blind, parallel-group, randomised controlled trial aims to recruit 118 participants from community pharmacies in Aotearoa New Zealand. Participants will be randomised 1:1 to receive topical cream with 2% ECMT-154 or vehicle control, and will apply assigned treatment twice daily to affected areas for six weeks. The primary outcome is improvement in subjective symptoms, assessed by change in POEM score. Secondary outcomes include change in objective symptoms assessed by SCORAD (part B), PO-SCORAD, DLQI, and treatment acceptability assessed by TSQM II and NRS. DISCUSSION Recruitment through community pharmacies commenced in January 2022 and follow up will be completed by mid-2023. This study aims to collect acceptability and efficacy data of mānuka oil based ECMT-154 for the treatment of eczema. If efficacy is demonstrated, this topical may provide an option for a novel emollient treatment. The community-based design of the trial is anticipated to provide a generalisable result. ETHICS AND DISSEMINATION Ethics approval was obtained from Central Health and Disability Ethics Committee (reference: 2021 EXP 11490). Findings of the study will be disseminated to study participants, published in peer-reviewed journal and presented at scientific conferences. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12621001096842. Registered on August 18, 2021 ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382412&isReview=true ). PROTOCOL VERSION 2.1 (Dated 18/05/2022).
Collapse
Affiliation(s)
- Gabrielle Shortt
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand.
- Victoria University of Wellington, Wellington, Aotearoa, New Zealand.
| | - Nicholas Shortt
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
- Victoria University of Wellington, Wellington, Aotearoa, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| | - Georgina Bird
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
| | - Kyley Kerse
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
| | - Nico Lieffering
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
| | - Alexander Martin
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
- Victoria University of Wellington, Wellington, Aotearoa, New Zealand
| | - Allie Eathorne
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| | - Bianca Black
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
| | - Bob Kim
- Anderson's Exchange Pharmacy, Dunedin, Aotearoa, New Zealand
| | - Marius Rademaker
- Waikato Clinical Campus, University of Auckland, Hamilton, Aotearoa, New Zealand
- New Zealand Dermatology Research Trust, Palmerston North, Aotearoa, New Zealand
| | - Louise Reiche
- New Zealand Dermatological Society Inc, Palmerston North, Aotearoa, New Zealand
- New Zealand Dermatology Research Trust, Palmerston North, Aotearoa, New Zealand
| | - Selwyn Te Paa
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
- University of Otago, Wellington, Aotearoa, New Zealand
| | - Suki Harding
- Manuka Bioscience Ltd, Auckland, Aotearoa, New Zealand
| | - Mike Armour
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| | - Alex Semprini
- Medical Research Institute of New Zealand, Wellington, Aotearoa, New Zealand
- Victoria University of Wellington, Wellington, Aotearoa, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| |
Collapse
|
2
|
Kim S, Lee YS, Yeo J, Lee D, Ko DK, Ha IH. Healthcare utilization for atopic dermatitis: An analysis of the 2010-2018 health insurance review and assessment service national patient sample data. PLoS One 2023; 18:e0286449. [PMID: 37363912 DOI: 10.1371/journal.pone.0286449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 05/16/2023] [Indexed: 06/28/2023] Open
Abstract
This cross-sectional, retrospective, observational study aimed to analyze the distribution and healthcare usage patterns of patients with atopic dermatitis using the 2010-2018 Health Insurance Review and Assessment Service data. Patients diagnosed with atopic dermatitis in Korea between January 2010 and December 2018 and registered in the Health Insurance Review and Assessment national database were identified, and 270,008 patients who used healthcare services at least once during this period were evaluated to ascertain the healthcare usage patterns and treatment methods for atopic dermatitis. The number of patients with atopic dermatitis plateaued during the study period, while the number of claims and total expenses increased by a small margin. Atopic dermatitis prevalence was the highest among patients aged <5 years (31.4%), followed by those aged 5-14 years (23.53%) and 15-24 years (15.33%). However, the prevalence in these age groups showed a decreasing trend over time. The most used Western medicine treatments were injections and oral medications involving topical corticosteroids, antihistamine agents, and oral steroids, while it was acupuncture therapy in Korean medicine. The frequency of the most frequently prescribed medication, topical corticosteroid, showed a decreasing trend over time. The findings in this study will inform healthcare policy makers and clinicians across different countries on the usage trends of Western medicine and Korean medicine treatment.
Collapse
Affiliation(s)
- Sowon Kim
- Jaseng Hospital of Korean Medicine, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea
| | - Ye-Seul Lee
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea
| | - Jiyoon Yeo
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea
| | - Donghyo Lee
- Department of Ophthalmology, Otolaryngology, and Dermatology, College of Korean Medicine, Woo-Suk University, Jeonju, Korea
| | - Dong Kun Ko
- Jayeonsaeng Korean Medicine Clinic, Yongin, Korea
| | - In-Hyuk Ha
- Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Gangnam-daero, Gangnam-gu, Seoul, Republic of Korea
| |
Collapse
|
3
|
O'Connor C, McCarthy S, Murphy M. Pooling the evidence: A review of swimming and atopic dermatitis. Pediatr Dermatol 2023; 40:407-412. [PMID: 37029288 PMCID: PMC10946598 DOI: 10.1111/pde.15325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Accepted: 03/28/2023] [Indexed: 04/09/2023]
Abstract
Swimming is an excellent form of aerobic exercise and is an essential life skill. Many children with atopic dermatitis (AD) are advised not to swim because of concerns about negative impacts on their skin disease, and some children with AD do not swim because they are self-conscious about the appearance of their skin. We aimed to perform a narrative review of the available literature on swimming and AD and scientifically analyze the potential impact of all components of swimming in AD-water, skin barrier, swimming gear, and exercise. Studies examined the impact of swimming on the skin barrier and the relative contraindications to swimming. Constituents of water which may affect AD include hardness, pH, temperature, antiseptics, and other chemicals. Potential interventions to reduce damage included emollient application, special swim gear, and showering post-submersion. The benefits of swimming as a form of exercise in AD included reduced sweating, cardiorespiratory fitness, and maintenance of healthy weight. Drawbacks of swimming as a form of exercise in AD included the limited benefit on bone mineral density. Future research should examine the impact of swimming on flares of AD using noninvasive biomarkers as well as clinical severity assessment and assess the role for different types of emollient as an intervention for optimal eczema control. This review highlights gaps in the scientific literature on swimming and AD and provides evidence-based guidance on interventions to minimize deleterious effects on skincare and maximize opportunities for children with AD to swim.
Collapse
Affiliation(s)
- Cathal O'Connor
- DermatologySouth Infirmary Victoria University HospitalCorkIreland
- Paediatrics and Child HealthCork University HospitalCorkIreland
- MedicineUniversity College CorkCorkIreland
- INFANT Research CentreUniversity College CorkCorkIreland
| | - Siobhan McCarthy
- DermatologySouth Infirmary Victoria University HospitalCorkIreland
- MedicineUniversity College CorkCorkIreland
| | - Michelle Murphy
- DermatologySouth Infirmary Victoria University HospitalCorkIreland
- MedicineUniversity College CorkCorkIreland
| |
Collapse
|
4
|
Shortt N, Martin A, Kerse K, Shortt G, Vakalalabure I, Barker L, Singer J, Black B, Liu A, Eathorne A, Weatherall M, Rademaker M, Armour M, Beasley R, Semprini A. Efficacy of a 3% Kānuka oil cream for the treatment of moderate-to-severe eczema: A single blind randomised vehicle-controlled trial. EClinicalMedicine 2022; 51:101561. [PMID: 35865740 PMCID: PMC9294249 DOI: 10.1016/j.eclinm.2022.101561] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 06/26/2022] [Accepted: 06/27/2022] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Māori, the indigenous people of New Zealand, have traditionally used the kānuka tree as part of their healing system, Rongoā Māori, and the oil from the kānuka tree has demonstratable anti-inflammatory and anti-bacterial properties. This trial investigated the efficacy and safety of a 3% kānuka oil (KO) cream compared to vehicle control (VC) for the topical treatment of eczema. The trial was conducted through a nationwide community pharmacy research network. METHODS This single-blind, parallel-group, randomised, vehicle-controlled trial was undertaken in 11 research trained community pharmacies across New Zealand. Eighty adult participants with self-reported moderate-to-severe eczema, assessed by Patient Orientated Eczema Measure (POEM) were randomised by blinded investigators to apply 3% KO cream or VC topically, twice daily, for six weeks. Randomisation was stratified by site and eczema severity, moderate versus severe. Primary outcome was difference in POEM scores at week six between groups by intention to treat. The study is registered on the Australian New Zealand Clinical Trial Registry (ANZCTR) reference number, ACTRN12618001754235. FINDINGS Eighty participants were recruited between 17 May 2019 and 10 May 2021 (41 KO group, 39 VC group). Mean POEM score (standard deviation) improved between baseline and week six for KO group, 18·4 (4·4) to 6·8 (5·5), and VC group, 18·7 (4·5) to 9·8 (6·5); mean difference between groups (95% confidence interval) was -3·1 (-6·0 to -0·2), p = 0·036. There were three adverse events reported in the KO group related to the intervention and two in the control group. INTERPRETATION The KO group had a significant improvement in POEM score compared to VC. Rates of adverse events and withdrawals were similar between groups with no serious adverse events reported. Treatment acceptability was high for both groups across all domains. Our results suggest that in adults with moderate-to-severe eczema, the addition of KO to a daily emollient regimen led to a reduction in POEM score compared to VC. KO may represent an effective, safe, and well tolerated treatment for moderate-to-severe eczema in adults. FUNDING Hikurangi Bioactives (Ruatoria, New Zealand) and HoneyLab (Tauranga, New Zealand), supported by a grant from Callaghan Innovation.
Collapse
Affiliation(s)
- Nicholas Shortt
- Medical Research Institute of New Zealand, Wellington, New Zealand
- Victoria University of Wellington, Wellington, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
- Corresponding author at: Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242, New Zealand.
| | - Alexander Martin
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Kyley Kerse
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Gabrielle Shortt
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Iva Vakalalabure
- Medical Research Institute of New Zealand, Wellington, New Zealand
- Te Marae Ora (Ministry of Health), Rarotonga, Cook Islands
| | - Luke Barker
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Joseph Singer
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Bianca Black
- Medical Research Institute of New Zealand, Wellington, New Zealand
| | - Angela Liu
- Alexander Pharmacy, Wellington, New Zealand
| | - Allie Eathorne
- Medical Research Institute of New Zealand, Wellington, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| | | | | | - Mike Armour
- Medical Research Institute of New Zealand, Wellington, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| | - Richard Beasley
- Medical Research Institute of New Zealand, Wellington, New Zealand
- Victoria University of Wellington, Wellington, New Zealand
| | - Alex Semprini
- Medical Research Institute of New Zealand, Wellington, New Zealand
- Victoria University of Wellington, Wellington, New Zealand
- NICM Health Research Institute, Western Sydney University, Penrith, Australia
| | | |
Collapse
|
5
|
Akbaş A, Emeksiz ZŞ, Yorulmaz A, Hayran Y, Kılınç F, Yakut HI, Toyran M, Demir Kİ. Complementary and Alternative Treatment Methods Practiced by Parents in Pediatric Cases Diagnosed with Atopic Dermatitis. J DERMATOL TREAT 2022; 33:3014-3021. [PMID: 35775854 DOI: 10.1080/09546634.2022.2097159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
INTRODUCTION Atopic Dermatitis (AD) is a chronic, recurrent and inflammatory skin disease experienced mostly in childhood. Chronicity of the disease, relapses, constant need of regular skin care causes seeking for alternative treatments. AIM The aim of this study is to evaluate the complementary and alternative treatments (CAT) used by parents' caregivers in pediatric patients diagnosed with AD, and the association between CAT use and patient characteristics. MATERIALS AND METHODS A questionnaire questioning the sociocultural and demographic characteristics of the family, the clinical findings of the patients, their treatments and CAT applications was recorded. RESULTS 83 patients were included in the study. 68.7% of the patients used at least 1 type of CAT. Vitamins and oils were the most commonly used CATs (48.8% and 47%, respectively) and 73.3% of the patients using CAT continued normal AD treatment while using CAT. The biggest factor affecting CAT choice was the advice of the immediate circle (75%), and 40.6% of the patients stated that they benefited from the complementary therapy. CONCLUSION CATs are widely used in AD. Physicians should know the socio-cultural structure of the region they are in, the CATs used and their side effects, and inform the families.
Collapse
Affiliation(s)
- Ayşe Akbaş
- Associate professor, Ankara City Hospital, Dermatology, Ankara, Turkey
| | - Zeynep Şengül Emeksiz
- Ankara City Hospital, Pediatric Allergy and Immunology Clinic specialist doctor Ankara, Turkey
| | - Ahu Yorulmaz
- Associate professor, Ankara City Hospital, Dermatology, Ankara, Turkey
| | - Yıldız Hayran
- Associate professor, Ankara City Hospital, Dermatology, Ankara, Turkey
| | - Fadime Kılınç
- Associate professor, Ankara City Hospital, Dermatology, Ankara, Turkey
| | | | - Müge Toyran
- Professor, Ankara City Hospital, Pediatric Allergy and Immunology Clinic Ankara, Turkey
| | - Kezban İpek Demir
- Ankara City Hospital, Pediatric Allergy and Immunology Clinic specialist doctor Ankara, Turkey
| |
Collapse
|
6
|
Ayasse MT, Ahmed A, Espinosa ML, Walker CJ, Yousaf M, Thyssen JP, Silverberg JI. What are the highest yielding search strategy terms for systematic reviews in atopic dermatitis? A systematic review. Arch Dermatol Res 2021; 313:737-750. [PMID: 33221950 DOI: 10.1007/s00403-020-02165-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 10/16/2020] [Accepted: 10/30/2020] [Indexed: 12/30/2022]
Abstract
The impact of search strategies on systematic reviews (SR) of atopic dermatitis (AD) is unknown. The purpose of this review was to evaluate search strategies used in SR of AD and their impact on the frequency of manuscripts identified. MEDLINE and EMBASE were searched for SR related to AD. Simulations were performed by running combinations of search terms in MEDLINE and EMBASE. Overall, 250 SR met inclusion criteria, of which 225 specified search strategies. SR using 5-6 terms (20.0% to 12.1%) or ≥ 7 (40.0% to 18.8%) terms decreased, whereas SR using 3-4 terms numerically increased (18.8% to 30.2%) and 1-2 terms remained similar (37.5% to 38.9%) from 1999-2009 to 2015-2019. The most commonly searched terms were "atopic dermatitis" (n = 166), followed by "eczema" (n = 156), "dermatitis atopic'" (n = 81), "atopic eczema" (n = 74), "neurodermatitis" (n = 59), "Besniers prurigo" (n = 29), "infantile eczema" (n = 27), and "childhood eczema" (n = 19). Simulations revealed that "eczema" and "atopic dermatitis" yielded the most hits. The number of search terms that maximized hits in MEDLINE and EMBASE was 5 and 4, respectively. Search strategies for AD were heterogeneous, with high proportions of search strategies providing few search hits. Future studies should use standardized and optimized search terms.
Collapse
Affiliation(s)
- Marissa T Ayasse
- Department of Dermatology, The George Washington University School of Medicine and Health Sciences, 2150 Pennsylvania Avenue NW, Suite 2B-425, Washington, DC, 20037, USA
| | - Adnan Ahmed
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Maria L Espinosa
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Christina J Walker
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Muhammad Yousaf
- Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Jacob P Thyssen
- Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| | - Jonathan I Silverberg
- Department of Dermatology, The George Washington University School of Medicine and Health Sciences, 2150 Pennsylvania Avenue NW, Suite 2B-425, Washington, DC, 20037, USA.
| |
Collapse
|
7
|
Abstract
Background Atopic dermatitis (AD) is associated with considerable financial cost. However, the full burden of out-of-pocket (OOP) expenses is not well understood. Objective We sought to characterize the OOP health care expenses associated with AD management. Methods A 25-question voluntary online survey was administered to National Eczema Association members worldwide (n = 113,502). Inclusion criteria (US residents age ≥18 years who either self-reported had AD or were primary caregivers of individuals with AD) were met by 77.3% (1118/1447) of respondents. Results Respondents reported OOP expenses in 3 categories: (1) health care providers and prescriptions, including health care provider visit deductibles (68.7% [686]), prescription co-pays (64.3% [635]), and prescriptions not covered by insurance (48.6% [468]); (2) nonprescription health care products, including moisturizers (94.3% [934]), hygiene products (85.0% [824], allergy medications (75.1% [715]), itch relievers (68.25% [647]), dietary supplements (52.2% [491]), and sleep aids (37.0% [336]); and (3) complementary approaches, including cleaning products (74.7% [732]), clothing/bedding (44.8% [430]), alternative medications (19.0% [180]), and adjunctive therapies (15.9% [150]). The median annual AD OOP expense was US $600 (range, US $0–$200,000), with 41.9% (364) reporting expenditures US $1000 or greater. Conclusions Out-of-pocket expenses place a significant financial burden on individuals with AD. Additional studies are needed to better understand associations and impact of OOP costs.
Collapse
|
8
|
Jones VA, Patel PM, Wilson C, Wang H, Ashack KA. Complementary and alternative medicine treatments for common skin diseases: A systematic review and meta-analysis. JAAD Int 2021; 2:76-93. [PMID: 34409356 PMCID: PMC8362305 DOI: 10.1016/j.jdin.2020.11.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/16/2020] [Indexed: 12/16/2022] Open
Abstract
Background Complementary and alternative medicine (CAM) treatments are growing in popularity as alternative treatments for common skin conditions. Objectives To perform a systematic review and meta-analysis to determine the tolerability and treatment response to CAM treatments in acne, atopic dermatitis (AD), and psoriasis. Methods PubMed/Medline and Embase databases were searched to identify eligible studies measuring the effects of CAM in acne, AD, and psoriasis. Effect size with 95% confidence interval (CI) was estimated using the random-effect model. Results The search yielded 417 articles; 40 studies met the inclusion criteria. The quantitative results of CAM treatment showed a standard mean difference (SMD) of 3.78 (95% CI [−0.01, 7.57]) and 0.58 (95% CI [−6.99, 8.15]) in the acne total lesion count, a SMD of −0.70 (95% CI [−1.19, −0.21]) in the eczema area and severity index score and a SMD of 0.94 (95% CI [−0.83, 2.71]) in the scoring of atopic dermatitis score for AD, and a SMD of 3.04 (95% CI [−0.35, 6.43]) and 5.16 (95% CI [−0.52, 10.85]) in the Psoriasis Area Severity Index score for psoriasis. Limitations Differences between the study designs, sample sizes, outcome measures, and treatment durations limit the generalizability of data. Conclusions Based on our quantitative findings we conclude that there is insufficient evidence to support the efficacy and the recommendation of CAM for acne, AD, and psoriasis.
Collapse
Key Words
- AD, atopic dermatitis
- AV, aloe vera
- CAM, complementary and alternative medicine
- CCO, coconut oil
- GT, green tea
- PASI, psoriasis area and severity index
- SCORAD, scoring of atopic dermatitis
- SMD, standardized mean difference
- SSO, sunflower seed oil
- TCS, topical corticosteroid
- TLC, total lesion count
- TTO, tea tree oil
- acne vulgaris
- aloe vera
- atopic dermatitis
- coconut oil
- colloidal oatmeal
- complementary alternative medicine
- curcumin
- eczema
- green tea
- honey
- meta-analysis
- natural ingredients
- psoriasis
- shea butter
- sunflower seed oil
- systematic review
- tea tree oil
- turmeric
- witch hazel
Collapse
Affiliation(s)
- Virginia A. Jones
- Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois
| | - Payal M. Patel
- Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois
| | - Claire Wilson
- Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois
| | - Hongnan Wang
- Department of Mathematics, Statistics and Computer Science, University of Illinois at Chicago, Chicago, Illinois
| | - Kurt A. Ashack
- Department of Dermatology, University of Illinois at Chicago, Chicago, Illinois
- Dermatology Associates of West Michigan, Grand Rapids, Michigan
- Correspondence to: Kurt A. Ashack, MD, MHS, Dermatology Associates of West Michigan, 1740 East Paris Ave SE, Grand Rapids, MI 49546.
| |
Collapse
|
9
|
Lin V, Patel R, Wirtz A, Mannem D, Ottwell R, Arthur W, Cook C, Howard H, Wright D, Hartwell M, Vassar M. Evaluation of Spin in the Abstracts of Systematic Reviews and Meta-Analyses of Atopic Dermatitis Treatments and Interventions. Dermatology 2021; 237:496-505. [PMID: 34000718 DOI: 10.1159/000515299] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 12/25/2020] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Spin - the misrepresentation of a study's results - has been identified in abstracts of studies focused on a variety of disorders from multiple fields of medicine. OBJECTIVES This study's primary objective was to evaluate the abstracts of systematic reviews and meta-analyses focused on the treatment of atopic dermatitis for the nine most severe forms of spin. METHODS We systematically searched Embase and MEDLINE for systematic reviews of atopic dermatitis therapies. Screening and data extraction occurred in a masked, duplicate fashion. Each included study was evaluated for the nine most severe types of spin and other study characteristics. RESULTS Our searches retrieved 2,456 studies, of which 113 were included for data extraction. Spin was found in 74.3% of our included studies (84/113). Spin type 6 occurred most frequently (68/113, 60.2%). Spin types 1, 2, and 9 were not identified. All industry-funded systematic reviews contained spin in their abstract. The presence of spin was not associated with any specific study characteristics, including the methodological quality of the study. CONCLUSIONS Severe forms of spin were found in the majority of abstracts for systematic reviews of atopic dermatitis treatments. Steps should be taken to prevent spin to improve the quality of reporting in abstracts.
Collapse
Affiliation(s)
- Vanessa Lin
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Raahi Patel
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
- Arkansas Colleges of Health Education, Fort Smith, Arkansas, USA
| | - Alexis Wirtz
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
- Arkansas Colleges of Health Education, Fort Smith, Arkansas, USA
| | - Deepika Mannem
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
- Arkansas Colleges of Health Education, Fort Smith, Arkansas, USA
| | - Ryan Ottwell
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Wade Arthur
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Courtney Cook
- Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
| | | | - Drew Wright
- Samuel J. Wood Library & C.V. Starr Biomedical Information Center, Weill Cornell Medical College, New York, New York, New York, USA
| | - Micah Hartwell
- Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
- Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Matt Vassar
- Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| |
Collapse
|
10
|
Parke MA, Perez-Sanchez A, Zamil DH, Katta R. Diet and Skin Barrier: The Role of Dietary Interventions on Skin Barrier Function. Dermatol Pract Concept 2021; 11:e2021132. [PMID: 33614213 DOI: 10.5826/dpc.1101a132] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2020] [Indexed: 12/24/2022] Open
Abstract
Multiple research studies have examined the role of specific dietary interventions and their effects on skin barrier function. The skin barrier is one of the body's first lines of protection against environmental insults, and disruption of this natural line of defense can result in xerosis, irritation, chronic dermatitis, and other cutaneous effects. Multiple laboratory, animal, and human studies have demonstrated that certain dietary interventions have the potential to impact skin barrier function. Measurements of skin barrier function include stratum corneum hydration and transepidermal water loss. In this review, we examine this research and provide an overview of the effects of prebiotics, probiotics, fatty acids, and emerging research on other substances.
Collapse
Affiliation(s)
| | - Ariadna Perez-Sanchez
- Internal Medicine, University of Texas Health Science Center at San Antonio, TX, USA
| | | | - Rajani Katta
- Department of Dermatology, McGovern Medical School at UTHealth, Houston TX, USA
| |
Collapse
|
11
|
Akour A, Abuloha S, Mulakhudair AR, Kasabri V, Al-Tammemi AB. Complementary and alternative medicine for urinary tract illnesses: A cross-sectional survey in Jordan. Complement Ther Clin Pract 2021; 43:101321. [PMID: 33548746 DOI: 10.1016/j.ctcp.2021.101321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Revised: 01/09/2021] [Accepted: 01/25/2021] [Indexed: 11/25/2022]
Abstract
The aim of this study was to assess the extent of Complementary and Alternative Medicine (CAM) usage, especially herbal preparations, in treating urinary tract illnesses, and their perceived efficacy. This was a cross-sectional survey that used a convenience sample of 278 adults who reported having any form of urinary tract illness. During the last 3 months, 105 (37.8%) of participants had used CAM for various urinary tract conditions, of which, 87 (82.9%) used herbal remedies. Urinary tract infections (UTIs) were the most reported urinary condition (n = 77, 73.3%) among CAM users. The most commonly used herbs were, parsley (n = 54, 19.2%), followed by chamomile (n = 29, 10.4%), barley (n = 20, 7.4%) and ginger (n = 18, 6.7%).The study provides an overview of various CAM remedies used to treat urinary tract illnesses in the Jordanian society, which would draw attention to the necessity of conducting interventional studies to evaluate the efficacy and safety of CAMs in treating urinary tract illnesses, either as stand-alone or adjuvant treatment.
Collapse
Affiliation(s)
- Amal Akour
- Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman, Jordan; Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah Univeristy of Jordan, Amman, Jordan.
| | - Sumaya Abuloha
- Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman, Jordan
| | - Ali R Mulakhudair
- Department of Food Health and Nutrition, College of Food Science, Al-Qasim Green University, Babylon, Iraq
| | - Violet Kasabri
- Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman, Jordan
| | - Ala'a B Al-Tammemi
- Department of Epidemiology and Global Health, Faculty of Medicine, Umeå University, Umeå, Sweden; Doctoral School of Health Sciences, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
12
|
Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen J, Bruin‐Weller M, Vestergaard C, Seneschal J, Werfel T, Cork M, Kunz B, Fölster‐Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen D, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder J, Ring J. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34:2717-2744. [DOI: 10.1111/jdv.16892] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 07/10/2020] [Accepted: 07/23/2020] [Indexed: 02/06/2023]
Affiliation(s)
- A. Wollenberg
- Department of Dermatology and Allergy Ludwig‐Maximilian‐University Munich Germany
| | - S. Christen‐Zäch
- Pediatric Dermatology Unit Departments of Dermatology and Pediatrics Centre Hospitalier Universitaire Vaudois Lausanne Switzerland
| | - A. Taieb
- University of Bordeaux Bordeaux France
| | - C. Paul
- Department of Dermatology and Allergy Toulouse University and CHU Toulouse France
| | - J.P. Thyssen
- Department of Dermatology and Allergy Herlev‐Gentofte HospitalUniversity of Copenhagen Hellerup Denmark
| | - M. Bruin‐Weller
- National Expertise Center for Atopic Dermatitis Department of Dermatology and Allergology University Medical Center Utrecht The Netherlands
| | - C. Vestergaard
- Department of Dermatology Aarhus University Hospital Aarhus Denmark
| | - J. Seneschal
- Department of Dermatology National Reference Center for Rare Skin Diseases Bordeaux University Hospitals Bordeaux France
| | - T. Werfel
- Division of Immunodermatology and Allergy Research Department of Dermatology and Allergy Hannover Medical School Hannover Germany
| | - M.J. Cork
- Sheffield Dermatology Research IICDUniversity of Sheffield UK
| | - B. Kunz
- Dermatologikum Hamburg Hamburg Germany
| | - R. Fölster‐Holst
- Department of Dermatology and Allergy University Hospital Schleswig‐Holstein Kiel Germany
| | - M. Trzeciak
- Department of Dermatology, Venereology and Allergology Medical University of Gdansk Gdansk Poland
| | - U. Darsow
- Department of Dermatology and Allergy Biederstein Technische Universität München Munich Germany
- ZAUM – Center of Allergy & Environment Munich Germany
| | - Z. Szalai
- Department of Dermatology Heim Pál National Children’s Institute Budapest Hungary
| | - M. Deleuran
- Department of Dermatology Aarhus University Hospital Aarhus Denmark
| | - L. Kobyletzki
- School of Medical Sciences Lund University Malmö Sweden
- School of Medical Sciences Örebro University Örebro Sweden
| | - S. Barbarot
- Department of Dermatology CHU Nantes UMR 1280 PhAN INRA, F‐44000 Nantes Université Nantes France
| | - A. Heratizadeh
- Division of Immunodermatology and Allergy Research Department of Dermatology and Allergy Hannover Medical School Hannover Germany
| | - U. Gieler
- Department of Dermatology University of Gießen and Marburg GmbH Gießen Germany
| | - D.J. Hijnen
- Department of Dermatology Erasmus MC University Medical Center Rotterdam The Netherlands
| | - S. Weidinger
- Department of Dermatology and Allergy University Hospital Schleswig‐Holstein Kiel Germany
| | - L. De Raeve
- Department of Dermatology Universitair Ziekenhuis Brussel (UZB)Free University of Brussels (VUB) Brussels Belgium
| | - Å. Svensson
- Department of Dermatology Skane University Hospital Malmö Sweden
| | - D. Simon
- Department of Dermatology, Inselspital Bern University Hospital University of Bern Bern Switzerland
| | - J.F. Stalder
- Department of Dermatology CHU Nantes UMR 1280 PhAN INRAE, F‐44000 Nantes Université Nantes France
| | - J. Ring
- Department of Dermatology and Allergy Biederstein Technische Universität München Munich Germany
- Christiane‐Kühne Center for Allergy Research and Education (CK‐Care) Davos Switzerland
| | | |
Collapse
|
13
|
Siriyong T, Phungtammasan S, Jansorn S, Chonsongkram N, Chanwanitsakul S, Subhadhirasakul S, Voravuthikunchai SP. Traditional Thai herbal medicine as an alternative treatment for refractory chronic eczema. Explore (NY) 2020; 16:242-249. [DOI: 10.1016/j.explore.2019.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 09/03/2019] [Accepted: 10/07/2019] [Indexed: 11/28/2022]
|
14
|
Olabi B, Worboys S, Garland T, Grindlay DJC, Rogers NK, Harman KE. What’s new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies. Clin Exp Dermatol 2020; 45:980-985. [DOI: 10.1111/ced.14304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/21/2020] [Indexed: 12/26/2022]
Affiliation(s)
- B. Olabi
- Department of Dermatology Lauriston Building, Lauriston Place Edinburgh UK
| | - S. Worboys
- James Wigg Practice 2 Bartholomew Road London UK
| | - T. Garland
- Department of Dermatology Alexandra Wing, Broadgreen Hospital Liverpool UK
| | - D. J. C. Grindlay
- Centre of Evidence Based Dermatology University of Nottingham King’s Meadow Campus Nottingham UK
| | - N. K. Rogers
- Centre of Evidence Based Dermatology University of Nottingham King’s Meadow Campus Nottingham UK
| | - K. E. Harman
- Centre of Evidence Based Dermatology University of Nottingham King’s Meadow Campus Nottingham UK
| |
Collapse
|
15
|
Lu CL, Liu XH, Stub T, Kristoffersen AE, Liang SB, Wang X, Bai X, Norheim AJ, Musial F, Alræk T, Fonnebo V, Liu JP. Correction to: Complementary and alternative medicine for treatment of atopic eczema in children under 14 years old: a systematic review and meta-analysis of randomized controlled trials. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2019; 19:16. [PMID: 30642310 PMCID: PMC6332624 DOI: 10.1186/s12906-018-2421-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|